Eli Lilly and Company (NYSE:LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription,... ByInvesting ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Eli Lilly is just weeks away from launching ... but has initially been made available in vials only as Lilly waits for EU approval of the KwikPen format later this year. Northern Ireland still ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound ... to offer the lower-cost version of Zepbound (tirzepatide) made available in August.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Patients who bought stockpiles of alternative GLP-1 drugs online aren't sure what to do with them after learning that the compounding pharmacy that made them didn't have the right license.

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

A nurse at the med spa offered her 16 weeks of compounded tirzepatide, which is the active ingredient in Eli Lilly's Zepbound ... gotten nearly $3,000 worth of vials when he heard about the ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.